Published online September 1, 2004
PEDIATRICS Vol. 114 No. 3 September 2004, pp. 852-855 (doi:10.1542/peds.2003-0913-L)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ulrich, C. M.
Right arrow Articles by Wendler, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ulrich, C. M.
Right arrow Articles by Wendler, D.
Related Collections
Right arrow Tumors

COMMENTARY

Palliative Care: A Supportive Adjunct to Pediatric Phase I Clinical Trials for Anticancer Agents?

Connie M. Ulrich, PhD, RN, Christine Grady, PhD, RN and David Wendler, PhD

Department of Clinical Bioethics,
Warren G. Magnuson Clinical Center
National Institutes of Health
Bethesda, MD 20892

The first 300 words of the full text of this article appear below.

Hampering enrollment of children to phase I oncology research would dramatically impair the ability of investigators to develop new treatments to improve medical care for the pediatric cancer population. The variability in pediatric tumor response indicates a need for the development of new anticancer agents that specifically target varying histologies of malignancies.1 Aleska and Koren argue that "clinical trials may be the only way to determine the appropriate types of treatments for pediatric cancer."2 The primary scientific objectives of a phase I trial are to assess the safety and tolerability of tested agents, to identify the maximum-tolerated dose of the drug, and characterize the drug's pharmacokinetics.1,3–8 Secondarily, preliminary antitumor efficacy data are sought.1,3–8

However, enrolling children with cancer in phase I trials raises important ethical concerns. Although pediatric clinical investigators hope that participation in the phase I trials will help subjects, they are not meant to cure or even improve the condition of the child. Usually, however, they offer the only remaining treatment option for children with advanced cancer and thereby provide an important source of hope at a difficult time.

Similar to adult phase I trials, pediatric phase I trials generally have a 5% to 8% response rate.1,3–8 Thus, it may be questionably unreasonable to offer enrollment in pediatric phase I trials because the likelihood of risk and discomfort are disproportionate to the marginal benefit. These trials may raise unrealistic hopes of a cure, burden already sick children with potentially invasive procedures, compound suffering through chemotherapeutic and other associated drug side effects, and limit the opportunity for palliation. On the other hand, families may perceive even a low likelihood of benefit favorably, and ethically we ought to respect the family's prima facie right to make this determination. As Ackerman notes "adequately informed families may choose to participate in a . . . [Full Text of this Article]

Reprint requests to (C.M.U.) School of Nursing and Center for Bioethics, Room 357 NEB, 420 Guardian Dr, Philadelphia, PA 19104-6096. E-mail: culrich@nursing.upenn.edu




This article has been cited by other articles:


Home page
 Palliat MedHome page
L. Monterosso and L. J. Kristjanson
Supportive and palliative care needs of families of children who die from cancer: an Australian study
Palliative Medicine, January 1, 2008; 22(1): 59 - 69.
[Abstract] [PDF]